Brand Names For Devices Need To Be Disclosed In CMS Open Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed revision to Sunshine rule would bring reporting for devices in line with drugs and biologics, rather than allowing for general disclosures for Rx manufacturers.